Eylea Has Already Begun to Be Used by U.S. Retinal Specialists One Month Post-Launch, According to a Recent BioTrends Report
The LaunchTrends: Eylea Wave 1 report, which measures product uptake and commercial effectiveness at one month post launch, finds that 40% of surveyed retinal specialists have initiated trial on Regenerons Eylea, the newest treatment for wet age-related macular degeneration (wet AMD). One key advantage of Eylea over its main competitors, Genentechs Lucentis and Avastin, is the formal dosing schedule, which allows dosing every eight weeks following an initial three monthly doses...